Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.35 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244767 | 0.82 | L3MBTL1 (0.47) | CXCL8TSHRTHRATHRBL3MBTL1 | |
| SCHEMBL5665826 | 0.82 | CXCL8 (0.39) | CXCL8ALDH1A1TP53HTTTSHR | |
| SCHEMBL11608880 | 0.81 | CXCL8 (0.38) | CXCL8ALDH1A1TP53HTTTSHR | |
| SCHEMBL28299708 | 0.81 | MEN1 (0.39) | IDO1ALDH1A1HTTFOLH1TSHR | |
| SCHEMBL6031816 | 0.81 | PTGS2 (0.52) | ALDH1A1TSHR | |
| SCHEMBL30524282 | 0.79 | SERPINE1 (0.43) | ALDH1A1TP53TSHR | |
| SCHEMBL5696260 | 0.79 | SERPINE1 (0.43) | ALDH1A1TP53TSHR | |
| SCHEMBL11607227 | 0.78 | HPGD (0.47) | ALDH1A1TP53TSHRL3MBTL1 | |
| SCHEMBL8203649 | 0.78 | THRA (0.50) | THRATHRBNPSR1 | |
| SCHEMBL4172961 | 0.78 | ELANE (0.44) | ALDH1A1THRATHRBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8552174-B2 | Solutions, methods, and processes for deprotection of polynucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8202985-B2 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2001896-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | Agilent Technologies, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007112263-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1792909-A1 | Synthesis of polynucleotides | Agilent Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | IDO1 3029/4885CXCL8 3391/4885ALDH1A1 3649/4885 |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | POLN, NT5C3B, PCNA | IDO1 3505/4885CXCL8 2844/4885ALDH1A1 4074/4885 |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | POLN, POLRMT, POLM | IDO1 4164/4885CXCL8 1905/4885ALDH1A1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.